The mechanism FDA will use to restrict GLP-1 compounding is now on the record

In February, FDA announced it intended to restrict the supply of GLP-1 active ingredients feeding mass-marketed compounded weight-loss and diabetes drugs, without specifying the legal instrument it would use to do it. Three months later, the mechanism arrived: a Federal Register notice proposing that semaglutide, tirzepatide and liraglutide be permanently excluded from the list of bulk drug substances that outsourcing facilities are legally allowed to compound from [s1]. The public comment period on that proposal closed 30 July, after being extended once [s1, s2].

What the 503B Bulks List actually controls

Large-scale compounding pharmacies, known as outsourcing facilities and regulated under Section 503B of the Federal Food, Drug, and Cosmetic Act, may compound a drug from bulk active pharmaceutical ingredient in one of two circumstances: the finished drug is on FDA's official shortage list at the time of compounding, or the bulk ingredient itself appears on the 503B Bulks List because FDA has determined there is a legitimate clinical need for outsourcing facilities to use it [s1].

Semaglutide and tirzepatide have already exited FDA's shortage list — tirzepatide in December 2024 and semaglutide in February 2025 — which closed the shortage-based path to large-scale compounding for both. The 503B Bulks List proposal targets the remaining path. FDA's notice states plainly that, after review, the agency "did not identify sufficient clinical need for outsourcing facilities to compound these drugs from bulk substances" [s1]. If finalized as proposed, semaglutide, tirzepatide and liraglutide would be permanently excluded from that list, closing the second legal route to large-scale compounding of all three — regardless of future shortage status.

Why this is the answer to February's open question

FDA's February statement described an "intent" to restrict GLP-1 ingredient supply and warned of seizure and injunction for non-compliant actors, but left open whether the restriction would come as an import alert, an enforcement sweep, or a formal listing decision. The 503B Bulks List proposal, issued 2 May, is the formal listing decision. It is also the more durable of the available options: an import alert or enforcement action targets specific shipments or companies, while a permanent exclusion from the Bulks List changes the underlying legal status of compounding these three ingredients at scale, for every outsourcing facility, indefinitely — unless FDA later reverses course through the same rulemaking process.

The comment period and what happens next

FDA's original notice set a 30 June deadline for public comment [s1]. On 26 June, the agency published a second notice extending that deadline by 30 days, to 30 July, in response to a request for additional time [s2]. The extension notice does not identify who requested it or take a position on the merits of the underlying proposal; it addresses only the timeline [s2].

With the comment period now closed, FDA's next formal step would be to review submitted comments and issue a final determination — either confirming the exclusion, modifying it, or declining to finalize it. Neither notice sets a deadline for that determination, and FDA's rulemaking timelines on Bulks List decisions have historically varied from months to well over a year.

What is and isn't resolved

A comment period closing is not the same as a rule taking effect. Compounding of semaglutide, tirzepatide and liraglutide from bulk substances remains legally constrained under existing shortage-list rules regardless of this proposal's outcome, since both drugs are already off FDA's shortage list. What the 503B exclusion would add, if finalized, is a permanent bar — removing any possibility that a future shortage determination reopens the compounding pathway for these three ingredients specifically.

For patients currently using a compounded GLP-1 product obtained through a large-scale outsourcing facility, this notice does not itself change anything yet; it is a proposal under review, not a final rule. What it does establish is that the enforcement intent FDA signaled in February now has a specific, public, comment-tested regulatory vehicle behind it.

What to watch

Whether FDA's final decision — whenever it arrives — tracks the proposal as written or is narrowed in response to comments, particularly from telehealth and compounding industry groups likely to have submitted opposition. Whether Congress or industry litigation attempts to intervene before a final rule issues. And whether smaller, state-licensed 503A compounding pharmacies, which operate under different rules than the outsourcing facilities this notice addresses, become the next focus of attention if the 503B pathway closes. This is regulatory reporting, not medical guidance; questions about a specific prescription belong with a treating clinician.

Sources

• [s1] Federal Register / U.S. Food and Drug Administration, "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act," notice, 1 May 2026. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
• [s2] Federal Register / U.S. Food and Drug Administration, "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period," 26 June 2026. https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal